DGAP-News: Biotest AG: Biotest Group reports increase of EBIT
(firmenpresse) - DGAP-News: Biotest AG / Key word(s): Quarter Results
Biotest AG: Biotest Group reports increase of EBIT
08.05.2013 / 11:15
---------------------------------------------------------------------
PRESS RELEASE
Biotest Group reports increase of EBIT
- EBIT up 13.5% at EUR 11.8 million
- Sales increased to EUR 118.7 million
- Management Board confirms guidance
Dreieich, 8 May 2013. In the first three months of financial year 2013 the
Biotest Group was able to significantly increase sales again and achieve a
new quarterly sales record. In the reporting period the Group generated
revenues of EUR 118.7 million compared to EUR 107.7 million in the same
quarter of the previous year. This represents an increase of 10.2 %.
Profitability also increased significantly. Earnings before interest and
taxes (EBIT) increased in the reporting period by 13.5 % from EUR 10.4
million to EUR 11.8 million. The largest increase was generated by the
Plasma&Services segment, where EBIT increased by 83.3 % compared to
the first quarter of 2012.
The growth in sales was driven primarily by the international markets.
Whereas there was slight growth in Europe, sales in the US increased
significantly. The market launch of Bivigam(R) in February 2013 was the
main reason for the double-digit growth in this market.
The marketing authorisation of Bivigam(R) by the US Food and Drug
Administration (FDA) as well as the market launch of the product represent
important milestones for Biotest. The Biotest Group estimates a sales
potential of about USD 100 million over the medium to long term for this
immunoglobulin used to treat patients with primary humoral immune
deficiencies.
The business performance of the Biotest Group continues to be very
positive. For this reason the Management Board reaffirms its target of
increasing sales by 10 % to 15 % in the current year. The management
expects a similar increase in EBIT.
The three-months report is available on the company's website at
http://www.biotest.de/ww/de/pub/investor_relations/publikationen/quartalsb
erichte.cfm
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has about 1.800
employees worldwide. The preference shares of Biotest AG are listed in the
SDAXon the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations(at)biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
End of Corporate News
---------------------------------------------------------------------
08.05.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations(at)biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
210028 08.05.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.05.2013 - 11:15 Uhr
Sprache: Deutsch
News-ID 257429
Anzahl Zeichen: 3298
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 228 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Biotest AG: Biotest Group reports increase of EBIT"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotest AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
